I'm originally from Dublin but now live in Edinburgh
doxycycline purchase ?By ignoring price in their weighting methodology, the argument is essentially that they have built a better mousetrap. And at first blush, by looking at the historical outperformance of a fundamental index approach, it appears that they have. But a deeper dive reveals the dirty little secret of "smart beta," which is that it is simply benefitting from two factors already known to have enhanced performance in the past: value and small-cap tilts. As James Montier of GMO wrote in his December 2013 white paper, "When these strategies are corrected for their exposure to 'value' and 'small,' they exhibit no statistically significant outperformance compared to the cap weighted benchmark." Montier adds that isn't even a guarantee that value (cheap price to book) and small caps will "outperform independent of their pricing," and that now is a particularly inconvenient time to use smart beta as "both value and small have very unattractive expected returns in the U.S. on our data."